网站主页>>>研发精选>>>临床前CDMO研发筛选相关化合物
CDMO是Contract Development and Manufacturing Organization的缩写,即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药(特别是创新药)工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力,是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化:创新性合成路线设计、工艺参数优化. 2, 中试放大:实验室工艺向规模化生产的转化 3, 注册批生产:支持客户新药申报的验证批生产. 4, 商业化生产:药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测:2026年全球CDMO市场规模:预计达1,189亿美元 2033年全球CDMO市场规模:预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物,已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前,在多肽、ADC、CGT等新型药物赛道的驱动下,全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力,全球市占率有望持续提升,行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

示例图片

临床前CDMO研发化合物筛选

  • Tenofovir Disoproxil

    中文名称:替诺福韦酯
    CAS号:201341-05-1
    分子式: C19H30N5O10P 分子量: 519.44
    产品形式: Free Base
    研发状态: Recruiting
    研发用途: Chronic Hepatitis b Patients
    研究机构: Sohag University
    研发日期: April 15 2023
    研发阶段: --
    Tenofovir Disoproxil (Bis(POC)-PMPA, GS 4331) is a prodrug of tenofovir, which is metabolised intracellularly to its active anabolite tenofovir diphosphate, a competitive inhibitor of HIV-1 reverse transcriptase and terminates the growing DNA chain.

  • Triapine

    中文名称:(E)-2-((3-氨基吡啶-2-基)亚甲基水杨酰硫酰胺
    CAS号:200933-27-3
    分子式: C7H9N5S 分子量: 195.24
    产品形式: free base
    研发状态: Completed
    研发用途: Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Primary Central Nervous System Hodgkin Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Unspecified Adult Solid Tumor Protocol Specific; Waldenström Macroglobulinemia
    研究机构: National Cancer Institute (NCI)
    研发日期: Jun-06
    研发阶段: Phase 1
    Triapine (3-AP) is a potent ribonucleotide reductase (RNR) inhibitor with broad spectrum antitumor activity by inhibiting DNA synthesis. Phase 2.

  • Cilengitide trifluoroacetate

    中文名称:西仑吉肽TFA
    CAS号:199807-35-7
    分子式: C29H41F3N8O9 分子量: 702.68
    产品形式: Trifluoroacetat
    研发状态: Terminated
    研发用途: Gliomas
    研究机构: Martin-Luther-Universität Halle-Wittenberg; Merck KGaA Darmstadt Germany
    研发日期: Jan-12
    研发阶段: Phase 2
    Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

  • O6-Benzylguanine

    中文名称:O-6-苄基鸟嘌呤
    CAS号:19916-73-5
    分子式: C12H11N5O 分子量: 241.25
    产品形式: free base
    研发状态: Completed
    研发用途: Brain and Central Nervous System Tumors
    研究机构: National Cancer Institute (NCI)
    研发日期: Feb-06
    研发阶段: Phase 2
    O6-Benzylguanine (O6-BG) is a potent O6-alkylguanine DNA alkyltransferase (AGT) inactivator.

  • PRT543

    中文名称:7H-吡咯啧啶-4-胺,7-[(5R)-5-C-(4-氯苯基)-β-D-核呋喃糖]-
    CAS号:1989620-03-2
    分子式: C17H17ClN4O4 分子量: 376.79
    产品形式: free base
    研发状态: Completed
    研发用途: Relapsed/Refractory Advanced Solid Tumors; Relapsed/Refractory Diffuse Large B-cell Lymphoma; Relapsed/Refractory Myelodysplasia; Relapsed/Refractory Myelofibrosis; Adenoid Cystic Carcinoma; Relapsed/Refractory Mantle Cell Lymphoma; Relapsed/Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia
    研究机构: Prelude Therapeutics
    研发日期: February 11 2019
    研发阶段: Phase 1
    PRT543 is a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) with broad antitumor activity in vitro and in vivo. It also inhibits the methyltransferase activity of the PRMT5/MEP50 complex with an IC50 of 10.8 nM.

  • Atazanavir

    中文名称: 阿扎那韦
    CAS号:198904-31-3
    分子式: C38H52N6O7 分子量: 704.86
    产品形式: free base
    研发状态: Active not recruiting
    研发用途: HIV/AIDS; Tuberculosis
    研究机构: University of Liverpool; European and Developing Countries Clinical Trials Partnership (Funder); Joint Clinical Research Centre Kampala Uganda; University of Cape Town Cape Town South Africa; Infectious Diseases Institute Makerere University College of Health Sciences Kampala Uganda; University of Turin Turin Italy
    研发日期: October 30 2020
    研发阶段: Phase 2 : Phase 3
    Atazanavir (Latazanavir, Zrivada, Reyataz, BMS-232632) is an azapeptide and HIV-protease inhibitor that is used in the treatment of HIV infections and AIDS in combination with other anti-HIV agents. Atazanavir is a substrate and inhibitor of cytochrome P450 isozyme 3A (CYP3A4) and an inhibitor and inducer of P-glycoprotein.

  • 免费注册, 助力研发,生产, 销售.

    招募中心

    我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!

    即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.

    试运营阶段,所有广告业务5折优惠

    分类广告投放

    依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.

    客户展示

    示例图片
    优秀企业推荐
    ×

    通知